RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps Sigilon Therapeutics Inc. is a 'very-early stage' pre-clinical company that is in the conceptual development of a "bio-platform".
This decsion fot Eli Lilly to acquire such an early stage company for US$126 per share further demonstrates that Big Pharma is facing a looming patent cliff and is seeking to fill its therapeutic product pipleline BUT is having to move further up-stream in the product development process in order to obtain biological assets that are experiecing favorable treatment by the Inflation Reduction Act (IRA) as already outlined in earlier posts.
In contrast ONCY's bio-platform in pelareorep is in late-stage clinical development which joins those biological assets that are experiencing premium valuations and M&A / buy-out pricing.